# Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4

> **NCT07522697** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 48 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Inavolisib

## Key facts

- **NCT ID:** NCT07522697
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2030-05
- **Final completion:** 2030-05
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07522697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07522697, "Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07522697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*